Full history for every metric is available with a Kvantra account
LBT Innovations Limited (LBT.AX)
Key financial summary
Financials in AUD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 0 | 1 | 1 | 2 | 2 | 1 | 1 |
| Operating profit | AUD m | -5 | -5 | |||||
| Net profit | AUD m | -4 | -6 | -7 | -7 | -23 | -4 | -4 |
| EPS reported | AUD | -0.00 | -0.01 | |||||
| Operating cashflow per share | AUD | -0.00 | -0.00 | |||||
| Capex per share | AUD | 0.00 | 0.00 | |||||
| FCF per share | AUD | -0.00 | -0.00 | |||||
| Free cash flow | AUD m | -4 | -4 | |||||
| Net debt | AUD m | -1 | -1 | |||||
| Book value equity | AUD m | 2 | 2 | |||||
| Book value per share | AUD | 0.00 | 0.00 | |||||
| Number of shares | m | 938.43 | 755.46 | |||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 5.42 | 12.34 | |||||
| P/S LTM | x | 10.46 | 23.80 | |||||
| P/FCF LTM | x | -3.57 | -8.12 | |||||
| EV/EBITDA LTM | x | -3.45 | -7.24 | |||||
| EV/Sales LTM | x | 11.13 | 23.32 | |||||
| Earnings Yield LTM | % | -28.47% | -23.44% | |||||
| FCF Yield | % | -28.00% | -12.31% | |||||
| Quality | ||||||||
| ROE | % | -154.35% | -322.69% | |||||
| ROIC | % | -57.33% | -57.33% | |||||
| Operating margin | % | -377.39% | -377.39% | |||||
| Gross margin | % | -232.25% | -232.25% | |||||
| FCF/Sales | % | -292.91% | -292.91% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -41.09% | -41.09% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.15 | -1.15 | |||||
| Net Debt/EBITDA | x | -0.21 | -0.21 | |||||
| EBIT/Net interest | x | -12.22 | -12.22 | |||||
| Net debt/market cap | % | -4.60% | -2.02% | |||||
| Net debt/Equity | x | -0.25 | -0.25 | |||||
| Gross debt/equity | x | 1.32 | 1.32 | |||||
Company overview
LBT Innovations Limited is dedicated to conceiving, advancing, and bringing to market cutting-edge technological solutions for the healthcare and laboratory sectors. The company's operations span various international locations, including Australia, Switzerland, the United States, the United Kingdom, and Germany. Its offerings include MicroStreak, an automated system designed for streaking and inoculating culture plates, and the Automated Plate Assessment System (APAS), a foundational technology that streamlines the screening and interpretation of culture plates. The firm is also actively developing several other innovations: Automated Gram Strain Assessment, intended for the automated interpretation of gram stain image analysis; WoundVue, an AI-powered tool assisting clinicians with the evaluation and care of chronic wounds; Automated Plate Assessment System Pharma, which leverages sophisticated artificial intelligence image analysis algorithms to automatically identify microbial growth in environmental monitoring applications; and specialized devices capable of detecting biofilms within mammalian tissue. Established in 2004, LBT Innovations Limited maintains its headquarters in Adelaide, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
LBT Innovations Limited (LBT.AX)
LBT Innovations Limited is dedicated to conceiving, advancing, and bringing to market cutting-edge technological solutions for the healthcare and laboratory sectors. The company's operations span various international locations, including Australia, Switzerland, the United States, the United Kingdom, and Germany. Its offerings include MicroStreak, an automated system designed for streaking and inoculating culture plates, and the Automated Plate Assessment System (APAS), a foundational technology that streamlines the screening and interpretation of culture plates. The firm is also actively developing several other innovations: Automated Gram Strain Assessment, intended for the automated interpretation of gram stain image analysis; WoundVue, an AI-powered tool assisting clinicians with the evaluation and care of chronic wounds; Automated Plate Assessment System Pharma, which leverages sophisticated artificial intelligence image analysis algorithms to automatically identify microbial growth in environmental monitoring applications; and specialized devices capable of detecting biofilms within mammalian tissue. Established in 2004, LBT Innovations Limited maintains its headquarters in Adelaide, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free